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BARRIERS TO CONTINUOUS GLUCOSE MONITORING IN PEOPLE WITH 
TYPE 1 DIABETES: CLINICIAN PERSPECTIVES 
MONICA LANNING 
ABSTRACT 
INTRODUCTION: 
Type 1 diabetes (T1D) is a lifelong disease that requires regular injection of 
insulin and blood glucose (BG) monitoring. Many diabetes technologies have been 
created to assist in the management of T1D, including insulin pumps and Continuous 
Glucose Monitoring (CGM). These systems have been shown to decrease treatment 
distress and improve glycemic control. However, the uptake of these systems is low due 
to both cost and other barriers such as discomfort of wear or psychosocial aspects.  
METHODS: 
 A survey was administered to clinicians of people with diabetes to better 
understand their perception of patient related barriers to device use. This analysis 
compares two clusters of clinicians, named “Cautious” and “Ready” based on their 
readiness to promote CGM use in their patients. Both have positive attitudes towards 
technology, but the Cautious cluster perceives much higher barriers to device use in their 
patients than the Ready cluster. In this analysis, the individual barriers, prerequisites to 
CGM use, confidence in addressing barriers, and clinic staff resources are compared 
between clusters using independent means t-tests and Pearson chi-square analyses.  
RESULTS: 
		 v 
 Results indicate that the confidence in addressing the clinician-reported number 1 
rated barrier to CGM use was significantly lower in the Cautious cluster. Also, most 
individual barriers were perceived significantly more heavily by clinicians in the 
Cautious cluster. No significant difference was found in prerequisites to CGM use or 
clinic staff resources between the clusters. 
DISCUSSION: 
 Because no differences were found in clinician reported prerequisites to CGM use 
between clusters, it does not seem that the clinicians in the Cautious cluster expect more 
from their patients before using this technology. One possible explanation would be a 
clinical deficiency. However, since there was no difference in clinic staff resources, it is 
unlikely that the availability of these resources contributes to the increased perceived 
barriers. Thus, the problem may lie in the clinician themselves. One possible explanation 
for the increased perceived barriers by the Cautious cluster is their lack of confidence in 
addressing barriers. Our results show that the Cautious cluster is significantly less 
confident in addressing the #1 barrier their patients face to CGM use, which is most 
commonly listed as a cost-related barriers such as cost of the device or insurance status. 
One possible solution to this lack of confidence in clinicians is increased education on 
ways to address and coach patients on cost-related barriers.  
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INTRODUCTION 
 
 Type 1 diabetes (T1D) is an autoimmune disorder that attacks the beta cells of the 
pancreas and is due to a combination of genetic, biologic, and environmental factors 
(Atkinson & Eisenbarth, 2001). Most cases are diagnosed in children under the age of 18, 
but T1D can develop at any age (Daneman, 2006). According to the 2017 CDC report, 
9.3% of the US population has diabetes, and it is estimated that 5% of those cases are 
T1D (“National Diabetes Statistics Report | Data & Statistics | Diabetes | CDC,” 2017). 
The estimated prevalence of T1D in the US is between 2.6-3.4/1000 of the entire 
population (Menke et al., 2013), and 1/300 for children under the age of 18, with 
incidence increasing by 2-5% worldwide (Maahs, West, Lawrence, & Mayer-Davis, 
2010; Mayer-Davis et al., 2017). People with T1D need to inject insulin for the rest of 
their lives in order to keep their blood glucose (BG) levels in a specified range. Many 
devices and technologies have been created that assist in the delivery of insulin and BG 
monitoring, such as insulin pumps and continuous glucose monitoring (CGM) (Daneman, 
2006). 
Diabetes devices can be extremely beneficial to people with T1D. These devices 
have been shown to improve diabetes health outcomes, such as glycemic control, and 
reduce hypoglycemia in both adult and pediatric patients (Group, 2008; Weissberg-
Benchell, Antisdel-Lomaglio, & Seshadri, 2003; Scrimgeour et al., 2007). Diabetes 
device use has both psychological and physiological advantages to people with diabetes. 
Use of these devices tends to increase health-related quality of life, increase satisfaction 
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with treatment regimens, and decrease depression (Rubin & Peyrot, 2009; Benkhadra et 
al., 2017; Lukács, Sasvári, Török, & Barkai, 2016; McGrady, Laffel, Drotar, Repaske, & 
Hood, 2009). Insulin pumps and CGM have also been shown to improve glycemic 
control (Hermanides, Phillip, & DeVries, 2011; Sherr et al., 2016) and reduce long-term 
complications in people with diabetes (Zabeen et al., 2016). Common long-term 
complications of T1D affect major systems in the body including the kidneys, eyes, 
nerves, and cardiovascular system (Alberti & Zimmet, 1998). 
Despite these advantages to using diabetes devices, the uptake of these devices is 
low, especially for CGM. According to 2014 data from the Type 1 Diabetes Exchange, a 
large registry of people with T1D, 60% of people with diabetes use an insulin pump, and 
only 11% use CGM (Miller et al., 2015). Furthermore, there is less sustained use of CGM 
in younger people, especially adolescents with diabetes,  compared to adults (Wong et al., 
2014). Additionally, there are advancements being made to diabetes devices that integrate 
the insulin pump with a CGM to create a closed-loop, or artificial pancreas system that	
automates insulin delivery at high and low blood glucose levels  (Tauschmann & 
Hovorka, 2017). There are many barriers that may prevent people from using these 
diabetes technologies such as cost of the device, discomfort of wear, and social factors 
(Zgibor & Songer, 2001; Seereiner et al., 2010; Liberman & Buckingham, 2016). 
In addition to patient-reported barriers to device use, clinicians report their own 
barriers to prescribing diabetes devices (Tanenbaum, Adams, Hanes, et al., 2017). It is 
important to understand these barriers as clinicians are the gateway to technology use in 
people with diabetes, and some clinicians are reluctant to prescribe CGM (Lodwig, 
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Kulzer, Schnell, & Heinemann, 2014). People with diabetes receive both 
recommendations and prescriptions from their clinicians, and it is essential for clinicians 
to educate and support their patients on diabetes devices to promote sustained use, as the 
benefits of CGM technology are decreased with only periodic use (Scheiner et al., 2009).  
There are also clinician perceptions of patient barriers. Physicians sometimes 
assume that patients want to know less or are overwhelmed by too much information 
about their treatments (Nair et al., 2002). Clinicians for people with diabetes tend to 
perceive more barriers to device use, and rate these barriers as more significant than they 
actually are for adults with diabetes (Tanenbaum, Adams, Hanes, et al., 2017). It is 
important for clinicians to help patients develop realistic, and not overly high, 
expectations of the device so that they are not disappointed by the system upon initiation 
(Iturralde et al., 2017; Mamkin, Ten, Bhandari, & Ramchandani, 2008). It is also possible 
that clinicians expect various abilities or achievements from their patients before 
prescribing them with diabetes devices. There are additional psychosocial reasons why 
clinicians may be reluctant to support device use in their patients. For example, some 
studies show that psychosocial instability within the family, or lack of family support, 
may be good reasons to postpone initiation of insulin pump therapy in children with T1D 
(Weinzimer et al., 2004). It is also advised that caregivers be educated in carbohydrate 
counting, the basics of basal-bolus therapy, insulin kinetics, the effect of exercise on 
blood glucose levels, and more before insulin pump use (Phillip, Battelino, Rodriguez, 
Danne, & Kaufman, 2007). For CGM use, many clinicians expect their patients to have 
an understanding of blood glucose changes after meals, insulin action kinetics, insulin 
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stacking, and to do frequent blood glucose testing (Mastrototaro, Welsh, & Lee, 2010). It 
is also recommended that people using CGM systems have frequent clinic visits to 
review the data (Joubert & Reznik, 2012). These recommended prerequisites can help 
patients use their devices to the full potential, but not all clinics may have the ability to 
deliver this education in order to promote device use in their patients. 
In addition to clinician perception of patient barriers, clinicians may lack essential 
clinic resources to provide patients the education they need for diabetes device use, such 
as support staff. Also, extra clinic resources allow for more time for device training 
through CDEs or trained pump or CGM trainers, which is important to set realistic 
expectations of diabetes devices and promote continued use (Ives, Sikes, Urban, 
Stephenson, & Tamborlane, 2010), and consistent CGM use is necessary to improve 
glycemic control in people with T1D (Giani, Snelgrove, Volkening, & Laffel, 2017). It is 
also important for clinicians to have time to download and review data created by these 
devices with their patients in order to maximize benefits of use (Miele, Weiland, & 
Dungan, 2012; Ives et al., 2010). If the clinician does not have the time or resources to 
educate and review data with their patients, they may be less likely to recommend these 
devices to their patients.  
To better understand the clinician’s perspective on diabetes technology use, and to 
determine whether clinicians are part of the reason there are low rates of device use 
among people with diabetes, Tanenbaum et. al (2018) surveyed clinicians who care for 
people with type 1 diabetes (n=209). A cluster analysis was performed based on several 
different measures related to technology attitudes, clinic time, ability to stay current with 
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technology trends, and perceived patient barriers to CGM use. The cluster analysis 
divided clinicians with into three profiles based on differences in their responses in order 
to better understand differences between. The three profiles were named “Not ready”, 
“Cautious” and “Ready”, based on their “readiness” to increase uptake of CGM in their 
patients. The Ready and Cautious clusters both had positive attitudes towards technology 
in general and CGM, whereas the Not Ready cluster had negative attitudes. The Cautious 
group perceived their patients to face the most barriers to CGM of all three groups, and 
the Ready group perceived the fewest barriers. The Not Ready Cluster saw mostly type 2 
diabetes (T2D) patients and had the lowest percentage of T1D patients on CGM 
(Tanenbaum, Adams, Barley, et al., 2017). 
The aim of the current study is to compare the Cautious and Ready profiles. 
Despite the Cautious profile’s positive attitudes towards diabetes devices and technology 
in general, these clinicians perceived their patients to face the most barriers to diabetes 
device use. Analyzing these two clusters may uncover the ways in which the Ready 
cluster clinicians are succeeding in promoting CGM use in their patients, and determine 
how we can support clinicians in the Cautious cluster to increase CGM uptake even 
further. 
This study investigates four hypotheses about the Ready and Cautious clusters in 
order to understand why the Cautious cluster perceived higher barriers to device us in 
their patients. (1) The clinicians in the Cautious cluster will endorse individual barriers 
(cost, discomfort of wear, social pressures) more often than the clinicians in the Ready 
cluster. (2) The clinicians in the Cautious cluster will have fewer clinic resources such as 
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CGM trainers and CDEs available. (3) The Cautious cluster will have lower confidence 
in addressing the three barriers to CGM use they ranked as most prominent to their 
patients. (4) The Cautious cluster will expect more from their patients before CGM use 
such as ability to download data and perform frequent blood glucose (BG) monitoring. 
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METHODS  
 
 Data was collected by the Stanford University team (Hood, PI) and online surveys 
were completed by providers in the T1D Exchange Clinic Network, a group of 75 
endocrinology practices based in the United States, as well as dQ&A, a company that 
conducts market research through diabetes proprietary panels including educators and 
physicians. The survey took approximately 45 minutes to complete and was administered 
over a 6-month period in early 2016. Clinicians were offered a $75 gift card or the 
opportunity to donate this compensation directly to any desired nonprofit diabetes 
organization. Two hundred and nine clinicians participated in the survey. Initial results of 
this survey have been published (Tanenbaum, Adams, Hanes, et al., 2017). The Stanford 
University IRB approved all study procedures. This analysis focuses on a small subset of 
questions asked in a larger survey battery for clinicians, including other variables that led 
to the clustering of profiles. 
To control for type 1 errors when preforming multiple tests, the Benjamini-
Hochberg procedure was done with a false discovery rate (Q) of 0.05 and statistical 
significance was determined (Benjamini & Hochberg, 1995). In tables (see Appendix), 
bolded results are statistically significant. This was done within each aim. 
Measures: 
Demographic and Clinical Practice Characteristics: Clinician demographic items 
included age range, race/ethnicity, gender, and personal relation to diabetes (whether they 
have diabetes themselves or a family member with diabetes). Clinical practice 
characteristics include practice type (academic, community, solo, etc.), practice setting 
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(urban, suburban, or rural), and years in profession. Clinicians reported their age within 
age ranges (<26 years, 26-35, 36-45, 46-55, 56-65, and >65). Patient population 
characteristics were also reported by clinicians, including number of patients with type 1 
vs. type 2 in their practice, percent of patients seen who are adult (18+) vs. pediatric, race 
and ethnicity percentages, percent of patients on public insurance, and percent using 
interpreter.  
Barriers: Clinicians were asked what barriers their patients face, or what they 
think their patients would say gets in the way of using CGM.  Barriers were listed (Table 
B2), and clinicians chose as many as they found applicable. Barriers listed covered both 
cost related (non-modifiable) barriers, such as “Insurance coverage”; and other 
(modifiable) barriers to CGM use, such as “Do not like having diabetes devices on their 
body”. 
Clinic Resources Available: Clinicians were asked about the staff resources 
available to assist their patients in clinic. They chose from a list of “All clinical resources 
to which your practice currently has easy access for your patients with diabetes”. There 
were 11 items including diabetes educators, mental health professionals, support staff, 
and specialists. Participants chose as many items from the list as applicable. Clinic 
resources were summed, with a higher score indicating more clinic resources available to 
clinicians (Range = 0-11). 
Confidence in Addressing Top Three Barriers: After selecting all possible barriers 
to CGM use, clinicians were asked to select the top three barriers to CGM use that their 
patients experience, ranked from #1 to #3. Then, clinicians rated their confidence in 
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addressing each of these barriers by themselves or through another provider in clinic on a 
scale of 1-10, with 1 indicating not confident, and 10 indicating extremely confident.  
Device Use Requirements: Clinicians selected from a list various achievements or 
prerequisites their patients need to meet before CGM use. Eight items covered topics 
such as treatment adherence, education, and social support. Some examples include 
“Perform frequent blood glucose monitoring”, “Have support from family or loved ones”, 
and “Have sufficient educational background”. Each of these items were ranked on a 
Likert scale, with 1 indicating “strongly disagree” and 5 indicating “strongly agree”. 
These scores were summed, with a lower score indicating less requirements for device 
use, and larger scores indicating more requirements for device use. These items are 
internally reliable (Cronbach’s alpha 0.813). 
Analysis: 
 Demographics: Frequencies, means, and standard deviations (SDs) were 
preformed to describe the total sample analyzed. Independent samples t-tests and Pearson 
chi-square analyses were performed to compare the clinician and patient population 
characteristics in the Ready and Cautious profiles.  
 Aim 1: Individual barriers to CGM use were compared between the Cautious and 
Ready profiles by conducing Pearson chi-square analyses. Total CGM barriers, total cost-
related (non-modifiable) barriers, and total modifiable barriers were analyzed using 
independent samples t-tests. 
Aim 2: To analyze clinic resources available to clinicians, the total number of 
resources indicated by each clinician was summed, and an independent samples t-test was 
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performed to compare means between the Cautious and Ready clusters. A Fisher’s Exact 
Test was then performed for the individual items “CGM trainers” and “Certified Diabetes 
Educators (CDEs)”, as these resources are relevant to diabetes device initiation and use in 
clinic. This test was chosen over a  Pearson chi-square analysis because the expected 
frequency of 25% of the cells was less than 5 (Field, 2009; Kim, 2017). 
Aim 3: Confidence ratings in addressing each of the top three barriers clinicians 
listed was summed, resulting in a possible range of 3-30. An independent samples t-test 
was performed to compare means between the Cautious and Ready clusters. Then, the 
confidence for the first, second, and third most relevant barriers listed were compared 
separately between the Cautious and Ready clusters with independent samples t-tests. 
Aim 4: Device use requirements was analyzed by preforming an independent 
samples t-test to compare means between the Cautious and Ready clusters. Then, an 
independent samples t-test was performed on each of the eight measures separately.  
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RESULTS 
 
Demographics: The total number of clinicians in the sample analyzed is 127, with 
42 (33.1%) in the Ready cluster, and 85 (66.9%) in the Cautious cluster. The age bracket 
of the total sample was 3.54, or approximately 45 years old. Approximately 16% of the 
clinicians in these clusters have T1D themselves, and 41.3% have a family member with 
T1D. The average years in profession was 12.67. For patient characteristics, an average 
of 40.69% were on public insurance and 8.29% of patients require an interpreter during 
clinic visits. Race and ethnicity of the patient population was reported as 64.84% white, 
19.32% Black, and 16.06% Hispanic. An average of 57.87% of patients seen by 
clinicians had T1D, with 41.82% of those patients being pediatric (<18). 
Independent samples t-tests and Pearson chi-square analyses was conducted to 
compare the Ready and Cautious clusters on several demographic variables. Table A1 
outlines the clinician and practice setting demographics of the Ready and Cautious group. 
The statistically significant differences found between the two clusters was the 
percentage of patients with T1D and the percent of pediatric patients seen in clinic and 
the total number of barriers endorsed. The Ready cluster’s patient population has a mean 
T1D percentage of 67.4% (SD=29.0), and the Cautious cluster sees an average of 53.3% 
(SD=33.6) of T1D patients in their clinic; t(124)=2.30, p = 0.023. The Ready cluster also 
sees more pediatric patients on average, with a mean percentage of 54.5% (SD=40.0) 
pediatric patients compared to the Cautious cluster’s mean percentage of 35.7% 
(SD=37.9); t(124)=2.552, p=0.012. 
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Aim 1: Almost all barriers listed were endorsed more frequently in the Cautious 
cluster than in the Ready cluster. Refer to Table B2, where statistically significant 
differences are bolded. The only barriers with no significant differences were “Nervous 
that the device might not work” and “Do not understand what to do with the information 
or features of the devices”. Total barriers, total cost-related barriers, and total modifiable 
barriers also showed a significant difference between clusters. This supports the 
hypothesis that clinicians in the Cautious cluster report most barriers to CGM use more 
often than clinicians in the Ready cluster. 
Aim 2: There was no significant difference found between the two clusters by the 
total number of clinic resources, CGM trainers, or CDEs available (Table C3). The mean 
total number of clinic resources was 7.4 for the Ready cluster (SD=2.2) and 7.5 for the 
Cautious cluster (SD=2.1); t(125)=-0.22, p=0.83. The percent of clinicians with CDEs 
available was 92.9% for the Ready group (SD=26.1) and 91.8 for the Cautious group 
(SD=27.7); c=0.046, p=1.00. While 92.9% (SD=26.1) of the Ready cluster has CGM 
trainers available in their clinic, only 85.9% (SD=35.0) of the Cautious cluster reports 
having this resource available, yet this difference was not significant; c=1.313, p=0.382. 
These results reject the hypothesis that the clinicians in the Cautious cluster have fewer 
staff resources than those in the Ready cluster. 
Aim 3: There was no statistically significant difference in total confidence ratings 
of clinicians addressing the top three barriers their patients face. The Ready cluster 
reports a mean confidence score of 17.7 (SD=7.5) and the Cautious cluster has a mean 
confidence score of 15.0 (SD=6.8; t(124)=1.99, p = 0.049. When analyzing clinician 
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confidence to address each of the three top barriers separately, the only significant 
difference between clusters was found for the first barrier. The confidence score means 
for the first barrier listed was 6.0 (SD=3.0) for the Ready cluster and 4.4 (SD=2.7) for the 
Cautious cluster, showing significantly lower confidence in the Cautious cluster; 
t(124)=3.06, p = 0.003. Results are found in Table D4. The hypothesis that the Cautious 
cluster is less confident in addressing the top three most pertinent barriers is partially 
supported by these results. 
Aim 4: No significant difference was found between the Cautious and Ready 
cluster in the total requirements for CGM use (Table E5). The Ready cluster reported a 
total mean requirement score of 26.6 (SD=4.9) and the Cautious cluster reports a mean of 
26.3 (SD=5.1); t(125)=0.37, p=0.715. There was also no significant difference found 
between clusters for each of the separate requirements. The hypothesis that the Cautious 
cluster expects more from their patients before CGM use is rejected by these results. 
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DISCUSSION 
 
 This analysis found several differences in the Cautious and Ready clinician 
profiles described by Tanenbaum et al. (Tanenbaum, Adams, Barley, et al., 2017). The 
significant findings from our analysis are that the Cautious cluster reports significantly 
lower confidence in addressing what they ranked as the most prominent barrier their 
patients face to using CGM. Also, the Cautious cluster reported their patients faced most 
of the individual barriers to CGM use significantly more often than the Ready cluster. 
 When asked to rank the top three barriers to insulin pump and CGM use, 
clinicians referred to cost-related, non-modifiable barriers most often (Tanenbaum, 
Adams, Hanes, et al., 2017). The Cautious cluster may be less confident in addressing 
cost-related barriers such as insurance coverage, cost of device, and cost of supplies, 
compared to the Ready cluster because they either do not have sufficient practice 
resources to do so or they feel these are hardest to address. Both adults and children with 
diabetes experience cost-related issues with treatments, and many pay high out of pocket 
costs (Piette, Heisler, & Wagner, 2004; Songer, LaPorte, Lave, Dorman, & Becker, 
1997). Also, many patients report that they have received little help or information from 
their clinicians with addressing high out of pocket treatment costs (Piette et al., 2004). 
However, there are steps that can be taken to receive insurance coverage, and many 
programs to help people with diabetes afford their supplies (Horswell, Wascom, Cerise, 
Besse, & Johnson, 2008; Strum, Hopkins, West, & Harris, 2005; ADA, n.d.).  
 Clinicians may benefit from training on new or novel methods of ways to address 
these cost-related barriers in order to help their patients through the insurance approval 
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process. However, physicians are already limited on time to spend with patients (Yarnall, 
Pollak, Østbye, Krause, & Michener, 2003). One way to relieve this burden is through 
clinic staff resources such as CDEs and social workers. Although not significant, the 
Cautious cluster has less CGM trainers than the Ready cluster. A lack of clinic staff 
support could make it difficult for the clinician to deliver diabetes education as 
comprehensively as needed. It is also possible that staff resources available to the 
clinicians in the Cautious cluster have the same lack of clinic-based education in 
addressing cost-related barriers to diabetes device use. It may be beneficial to have clinic-
wide educational sessions in addressing these barriers and to refer to vetted online 
resources to complement in person trainings. More studies need to be done in order to 
determine the best method to educate or prepare clinicians to address cost related barriers. 
This analysis found no difference in clinician perceived requirements or prerequisites 
for CGM use. This means that the Cautious cluster does not expect more from their 
patients when using CGM than the Ready cluster. Therefore, the high barriers perceived 
by the Cautious cluster is likely not due to clinicians expecting more from their patients 
such as carbohydrate counting skills or frequent blood glucose (BG) monitoring. This, 
along with the fairly equal number of clinic staff resources, shows that the increased 
perception of barriers to CGM use represented by the Cautious cluster may be due to 
some other inadequacy in the clinic or the clinicians themselves. According to the cluster 
analysis by Tanenbaum et. al. (2018), the Cautious cluster found it somewhat more 
difficult to stay current with new diabetes technology compared to the Ready cluster. 
Also, the Cautious cluster reported having less clinic time to review device data and 
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adjust insulin doses than the Ready cluster. It is also possible that the clinicians are 
hesitant to address issues related to CGM use because they themselves do not feel as 
confident as they would like in addressing these barriers. These are all possible areas of 
intervention that may help decrease perceived barriers in the Cautious cluster.  
 The Ready cluster’s larger proportion of pediatric and T1D patients may mean 
that these clinicians have more time to work with patients, which may give them more 
experience in addressing barriers to CGM use. There is a significant shortage of adult 
endocrinologists, as compared to pediatric (Vigersky et al., 2014), which may give 
pediatric clinicians more time with their patients. Since the Ready cluster has a larger 
proportion of pediatric patients, they may have more time to address barriers during 
scheduled appointments. This may contribute to the decreased number of barriers 
perceived by the Ready cluster. Also, CGM is most widely used in the type 1 population 
(Foster et al., 2016). Since the Ready cluster has a larger type 1 diabetes patient 
population than the Cautious cluster, it is possible that they have had more exposure to 
these types of diabetes technologies. The increased exposure to CGM may reduce the 
barriers clinicians perceive their patients to face.  
 Almost all individual barriers were reported significantly more often in the 
Cautious cluster than in the Ready cluster. The only barriers that showed non-significant 
differences were “Nervous that the device might not work”, “Do not want to have more 
information about their diabetes”, and “Do not understand what to do with the 
information or features of the devices”. It seems that both clusters perceive the large 
amount of data given by CGM and the hesitation to trust a new device with their 
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treatment are prominent barriers to CGM use. Otherwise, all other barriers are perceived 
more frequently by the Cautious cluster clinicians.  
It is important to understand what barriers may be causing low use rates or 
diabetes devices because people with T1D are not fully realizing the benefit of the many 
advancements in diabetes technology. One of the major advancements in diabetes 
technology, the closed loop system, has the ability to decrease treatment distress and 
improve glycemic control even more than insulin pump and CGM therapy alone, 
especially in people with T1D (Sharifi et al., 2016). The use of closed loop systems has 
the outcome of increased time in target blood glucose range and decreased overnight 
hypoglycemia in adults with T1D compared to conventional insulin pump use (Hovorka 
et al., 2011). Increased time in target glucose range has the potential to reduce chronic 
diabetes complications (Russell, 2015). In adolescents, wearing a closed loop system 
reduced mean glucose level and time spent above glucose target, with no increase in daily 
insulin amount (Tauschmann, Allen, Wilinska, Thabit, Stewart, et al., 2016; Tauschmann, 
Allen, Wilinska, Thabit, Acerini, et al., 2016). Hopefully, by addressing barriers to CGM 
and pump use at the clinician level, we can prepare for the eventual production of these 
advanced systems and promote use in people with diabetes. 
There are several limitations to this analysis. An online survey was utilized to 
determine technology attitudes, which could skew the results to more tech savvy 
populations. Although this may result in an incomplete subset of the clinician 
demographic, the clusters still show differences among clinicians that can be addressed to 
increase CGM use. Furthermore, although the Cautious cluster reports high modifiable 
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and non-modifiable barriers among their patients, they also reported a similar percent of 
CGM users compared to the Ready cluster. Having higher barriers may mean that the 
Cautious cluster is more aware of patient difficulties in using CGM. However, the 
decreased confidence in addressing these barriers indicates that the Cautious cluster may 
still have the potential to increase CGM use in their patients with training in how to face 
these barriers. Finally, although we collected the percent of patient population on public 
insurance, no other measures on patient socioeconomic status were collected. It is 
possible that the Cautious group’s patient population truly faces more cost-related 
barriers to device use than the Ready group. However, perceived modifiable barriers were 
also high in the Cautious cluster, and can be unrelated to socioeconomic status. 
More work needs to be done to better understand how to empower and train clinicians 
in helping patient overcome cost and insurance-related barriers to diabetes device use, 
especially as advancements in diabetes technology continues. These technologies have 
the potential to improve outcomes for people with type 1 diabetes beyond what is capable 
today. By learning to overcome barriers to CGM and insulin pumps, clinicians may be 
more prepared to help their patients use closed loop systems as they become available. 
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APPENDIX A 
Table A2  
Patient and Clinician Demographics 
 Total 
Sample 
(SD) 
Cautious 
(SD) 
Ready 
(SD) 
P 
value 
t-score Degrees 
of 
freedom 
 Clinician Demographics 
% of total 
sample 
 
n=127 66.9% 
(n=85) 
33.1% 
(n=42) 
   
Clinician 
Age 
 
 
3.54 (1.258) 3.59 (1.256) 3.45 
(1.273) 
0.569 t=-0.571 125 
Clinicians 
with T1D 
themselves 
 
15.9% 
(n=20) 
16.7% 
(n=14) 
14.3% 
(n=6) 
0.730 c=0.119 1 
Clinicians 
with family 
members 
with T1D 
 
41.3%  
(n=52) 
38.1% 
(n=32) 
47.6% 
(n=20) 
0.306 c=1.048 1 
Years in 
profession 
 
12.67 
(9.696) 
13.34 
(9.606) 
11.30 
(9.856) 
0.277 t=-1.093 120 
 Patient Demographics: 
% On 
public 
insurance 
 
40.69 
(21.055) 
39.4 
(21.738) 
43.34 
(19.571) 
0.327 t=0.984 123 
% 
Requiring 
interpreter 
 
8.29 
(10.071) 
8.49 
(11.378) 
7.88 
(6.750) 
0.752 t=-0.317 123 
%Black 
 
 
19.32 
(14.348) 
20.06 
(15.907) 
17.83 
(10.527) 
0.413 t=-0.821 125 
%White 
 
 
64.84 
(17.958) 
63.90 
(19.662) 
66.71 
(13.971) 
0.410 t=0.827 124 
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%Hispanic 
 
 
16.06 
(12.043) 
16.31 
(13.009) 
15.56 
(9.902) 
0.746 t=-0.325 123 
% Patients 
with T1D 
 
57.87 ± 
(32.735) 
53.3 (33.6) 67.4 (29.0) 0.023a t=2.295 124 
% Pediatric 
Patients 
with T1D 
 
41.82 
(39.462) 
35.73 
(37.932) 
54.47 
(40.024) 
0.012a t=2.552 124 
% Adult 
Patients 
with T1D 
58.18 
(39.462) 
64.27 
(37.932) 
45.53 
(40.024) 
0.012a t=-2.552 124 
aTests not significant with Benjamini-Hochberg adjustment 
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APPENDIX B 
Table B2  
Clinician Perceived Barriers to CGM Use 
 Experimental Groups    
Barrier Cautious (%) Ready (%) P value c2 Degrees of 
Freedom 
Total CGM Barriers 
 
9.906 
(SD=4.102) 
4.762 
(SD=2.046) 
0.000 t=-7.659 125 
Cost-Related CGM 
Barriers 
 
2.953 
(SD=0.213) 
1.405 
(SD=0.885) 
0.000 t=-
15.310 
125 
Cost of device 
 
85.7 14.3 0.000 68.423 1 
Cost of Supplies 
 
86.5 13.5 0.000 67.767 1 
Insurance Coverage 
 
72.4 27.6 0.000 18.202 1 
Modifiable CGM 
Barriers 
 
6.882 
(SD=4.007) 
3.310 
(SD=2.030) 
0.000 t=-5.436 125 
Nervous that the device 
might not work 
 
81.5 18.5 0.070 3.281 1 
Nervous to rely on 
technology 
 
81.0 19.0 0.018 5.575 1 
Too busy to learn how 
to use a new 
technology or device 
 
90.7 9.3 0.000 16.593 1 
Do not like having 
diabetes devices on 
their body 
 
72.8 27.2 0.022 5.245 1 
Do not like how 
diabetes devices look 
on their body 
 
80.4 19.6 0.015 5.944 1 
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Do not want to take 
more time from their 
day to manage diabetes 
 
85.4 14.6 0.002 9.298 1 
Do not want to have 
more information 
about their diabetes 
 
78.6 21.4 0.050 3.843 1 
Do not understand 
what to do with the 
information or features 
of the devices 
 
75.4 24.6 0.051 3.814 1 
Do not like diabetes 
devices because people 
notice them and ask 
questions about them 
 
81.6 18.4 0.022 5.258 1 
Do not want to share 
diabetes information 
with family members 
 
87.0 13.0 0.024 5.090 1 
Their family does not 
think diabetes devices 
are important for 
taking care of their 
diabetes 
 
87.0 13.0 0.024 5.090 1 
Too hard to get it to 
work right 
 
85.7 14.3 0.000 12.720 1 
Too many alarms 
 
75.3 24.7 0.004 8.125 1 
Causes discomfort or 
pain 
 
80.4 33.1 0.004 8.160 1 
Interferes with sleep 
 
86.0 14.0 0.000 13.551 1 
Not enough time 
during clinic visits to 
learn about how to use 
devices 
92.9 7.1 0.029 4.779 1 
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APPENDIX C 
Table C3 
Clinic Resources Available 
 Experimental Groups    
 Cautious (n) Ready (n) P value t-score Degrees of 
Freedom 
Total Clinic 
Resources (n) 
7.47 ± 2.13 7.38 ± 2.21 0.826 -0.220 125 
    Pearson 
chi-square 
Degrees of 
Freedom 
CGM trainers 
% 
85.9 92.9 0.382 1.313 1 
CDEs % 91.7 92.9 1.000 0.046 1 
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APPENDIX D 
Table D4 
Confidence in Addressing Barriers 
 Cautious (n) Ready (n) P value t-score Degrees of 
Freedom 
Confidence 
total 
 
15.0 ± 6.8 17.7 ± 6.8 0.049a 1.993 124 
Confidence #1 
 
4.4 ± 2.7 6.0 ± 2.9 0.003 3.057 124 
Confidence #2 
 
5.1 ± 2.9 6.1 ± 2.7 0.069 1.838 120 
Confidence #3 5.8 ± 2.6 6.5 ± 2.6 0.171 1.379 118 
a Test not significant with Benjamini-Hochberg adjustment 
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APPENDIX E 
Table E5 
Requirements for CGM Use 
 Cautious 
(n) 
Ready (n) P value t-score Degrees of 
Freedom 
Device use 
Requirements 
total (n) 
 
26.3 ± 5.1 26.6 ± 4.9 0.715 0.366 125 
Perform frequent 
BG monitoring 
 
3.32 3.52 0.331 0.976 125 
Be willing to 
change CGM 
sites frequently 
 
3.46 3.67 0.297 1.047 125 
Have frequent  
clinic visits, 
every 3-4 months 
 
3.81 4.02 0.309 1.347 124 
Download the 
CGM data 
 
3.80 3.57 0.202 -1.283 124 
Speak English 
 
2.18 2.07 0.524 -0.638 125 
Have support 
from family or 
loved ones 
 
3.38 3.36 0.909 -0.115 125 
Have sufficient 
educational 
background 
 
3.11 3.17 0.733 0.341 124 
Be willing to 
communicate 
openly about 
diabetes with 
family or loved 
ones 
3.34 3.33 0.964 -0.045 125 
	26 
LIST OF JOURNAL ABBREVIATIONS 
 
ADA 
CFP  
BMJ  
JCEM 
JDST 
JPEM 
NEJM  
RDE  
WJNR  
 
American Diabetes Association 
Canadian Family Physician 
British Medical Journal 
The Journal of Clinical Endocrinology and Metabolism 
Journal of Diabetes Science and Technology 
Journal of Pediatric Endocrinology and Metabolism 
New England Journal of Medicine 
Restorative Dentistry Endodontics 
Western Journal of Nursing Research 
  
	27 
REFERENCES 
 Alberti,	K.	g.	m.	m.,	&	Zimmet,	P.	z.	(1998).	Definition,	diagnosis	and	classification	of	diabetes	mellitus	and	its	complications.	Part	1:	diagnosis	and	classification	of	diabetes	mellitus.	Provisional	report	of	a	WHO	Consultation.	Diabetic	
Medicine,	15(7),	539–553.	doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S	American	Diabetes	Association.	(2017,	June	12).	Prescription	Assistance.	Retrieved	January	26,	2018,	from	http://www.diabetes.org/living-with-diabetes/health-insurance/prescription-assistance.html	Atkinson,	M.	A.,	&	Eisenbarth,	G.	S.	(2001).	Type	1	diabetes:	new	perspectives	on	disease	pathogenesis	and	treatment.	The	Lancet,	358(9277),	221–229.	doi:10.1016/S0140-6736(01)05415-0	Benjamini,	Y.,	&	Hochberg,	Y.	(1995).	Controlling	the	False	Discovery	Rate:	A	Practical	and	Powerful	Approach	to	Multiple	Testing.	Journal	of	the	Royal	
Statistical	Society.	Series	B	(Methodological),	57(1),	289–300.	doi:10.2307/2346101	Benkhadra,	K.,	Alahdab,	F.,	Tamhane,	S.	U.,	McCoy,	R.	G.,	Prokop,	L.	J.,	&	Murad,	M.	H.	(2017).	Continuous	subcutaneous	insulin	infusion	versus	multiple	daily	injections	in	individuals	with	type	1	diabetes:	a	systematic	review	and	meta-analysis.	Endocrine,	55(1),	77–84.	doi:10.1007/s12020-016-1039-x	
	28 
Daneman,	D.	(2006).	Type	1	diabetes.	Lancet	(London,	England),	367(9513),	847–858.	doi:10.1016/S0140-6736(06)68341-4	Field,	A.	(2009).	Discovering	Statistics	Using	SPSS	(3rd	ed.).	SAGE	Publications.	Foster,	N.	C.,	Miller,	K.	M.,	Tamborlane,	W.	V.,	Bergenstal,	R.	M.,	Beck,	R.	W.,	&	T1D	Exchange	Clinic	Network.	(2016).	Continuous	Glucose	Monitoring	in	Patients	With	Type	1	Diabetes	Using	Insulin	Injections.	Diabetes	Care,	39(6),	e81-82.	doi:10.2337/dc16-0207	Giani,	E.,	Snelgrove,	R.,	Volkening,	L.	K.,	&	Laffel,	L.	M.	(2017).	Continuous	Glucose	Monitoring	(CGM)	Adherence	in	Youth	With	Type	1	Diabetes:	Associations	With	Biomedical	and	Psychosocial	Variables.	Journal	of	Diabetes	Science	and	
Technology,	11(3),	476–483.	doi:10.1177/1932296816676280	Group,	T.	J.	D.	R.	F.	C.	G.	M.	S.	(2008).	Continuous	Glucose	Monitoring	and	Intensive	Treatment	of	Type	1	Diabetes.	New	England	Journal	of	Medicine,	359(14),	1464–1476.	doi:10.1056/NEJMoa0805017	Hermanides,	J.,	Phillip,	M.,	&	DeVries,	J.	H.	(2011).	Current	Application	of	Continuous	Glucose	Monitoring	in	the	Treatment	of	Diabetes.	Diabetes	Care,	34(Suppl	2),	S197–S201.	doi:10.2337/dc11-s219	Horswell,	R.	L.,	Wascom,	C.	K.,	Cerise,	F.	P.,	Besse,	J.	A.,	&	Johnson,	J.	K.	(2008).	Diabetes	Mellitus	Medication	Assistance	Program:	Relationship	of	Effectiveness	to	Adherence.	Journal	of	Health	Care	for	the	Poor	and	
Underserved,	19(3),	677–686.	doi:10.1353/hpu.0.0062	
	29 
Hovorka,	R.,	Kumareswaran,	K.,	Harris,	J.,	Allen,	J.	M.,	Elleri,	D.,	Xing,	D.,	…	Evans,	M.	L.	(2011).	Overnight	closed	loop	insulin	delivery	(artificial	pancreas)	in	adults	with	type	1	diabetes:	crossover	randomised	controlled	studies.	BMJ,	
342,	d1855.	doi:10.1136/bmj.d1855	Iturralde,	E.,	Tanenbaum,	M.	L.,	Hanes,	S.	J.,	Suttiratana,	S.	C.,	Ambrosino,	J.	M.,	Ly,	T.	T.,	…	Hood,	K.	K.	(2017).	Expectations	and	Attitudes	of	Individuals	With	Type	1	Diabetes	After	Using	a	Hybrid	Closed	Loop	System.	The	Diabetes	Educator,	
43(2),	223–232.	doi:10.1177/0145721717697244	Ives,	B.,	Sikes,	K.,	Urban,	A.,	Stephenson,	K.,	&	Tamborlane,	W.	V.	(2010).	Practical	aspects	of	real-time	continuous	glucose	monitors:	the	experience	of	the	Yale	Children’s	Diabetes	Program.	The	Diabetes	Educator,	36(1),	53–62.	doi:10.1177/0145721709352010	Joubert,	M.,	&	Reznik,	Y.	(2012).	Personal	continuous	glucose	monitoring	(CGM)	in	diabetes	management:	Review	of	the	literature	and	implementation	for	practical	use.	Diabetes	Research	and	Clinical	Practice,	96(3),	294–305.	doi:10.1016/j.diabres.2011.12.010	Kim,	H.-Y.	(2017).	Statistical	notes	for	clinical	researchers:	Chi-squared	test	and	Fisher’s	exact	test.	Restorative	Dentistry	&	Endodontics,	42(2),	152–155.	doi:10.5395/rde.2017.42.2.152	Liberman,	A.,	&	Buckingham,	B.	(2016).	Diabetes	Technology	and	the	Human	Factor.	
Diabetes	Technology	&	Therapeutics,	18(S1),	S-101.	doi:10.1089/dia.2016.2510	
	30 
Lodwig,	V.,	Kulzer,	B.,	Schnell,	O.,	&	Heinemann,	L.	(2014).	Current	Trends	in	Continuous	Glucose	Monitoring.	Journal	of	Diabetes	Science	and	Technology,	
8(2),	390–396.	doi:10.1177/1932296814525826	Lukács,	A.,	Sasvári,	P.,	Török,	A.,	&	Barkai,	L.	(2016).	Generic	and	disease-specific	quality	of	life	in	adolescents	with	type	1	diabetes:	comparison	to	age-matched	healthy	peers.	Journal	of	Pediatric	Endocrinology	and	Metabolism,	
29(7),	769–775.	doi:10.1515/jpem-2015-0397	Maahs,	D.	M.,	West,	N.	A.,	Lawrence,	J.	M.,	&	Mayer-Davis,	E.	J.	(2010).	Chapter	1:	Epidemiology	of	Type	1	Diabetes.	Endocrinology	and	Metabolism	Clinics	of	
North	America,	39(3),	481–497.	doi:10.1016/j.ecl.2010.05.011	Mamkin,	I.,	Ten,	S.,	Bhandari,	S.,	&	Ramchandani,	N.	(2008).	Real-time	continuous	glucose	monitoring	in	the	clinical	setting:	the	good,	the	bad,	and	the	practical.	
Journal	of	Diabetes	Science	and	Technology,	2(5),	882–889.	doi:10.1177/193229680800200520	Mastrototaro,	J.,	Welsh,	J.	B.,	&	Lee,	S.	(2010).	Practical	considerations	in	the	use	of	real-time	continuous	glucose	monitoring	alerts.	Journal	of	Diabetes	Science	
and	Technology,	4(3),	733–739.	doi:10.1177/193229681000400329	Mayer-Davis,	E.	J.,	Lawrence,	J.	M.,	Dabelea,	D.,	Divers,	J.,	Isom,	S.,	Dolan,	L.,	…	Wagenknecht,	L.	(2017).	Incidence	Trends	of	Type	1	and	Type	2	Diabetes	among	Youths,	2002–2012.	New	England	Journal	of	Medicine,	376(15),	1419–1429.	doi:10.1056/NEJMoa1610187	
	31 
McGrady,	M.	E.,	Laffel,	L.,	Drotar,	D.,	Repaske,	D.,	&	Hood,	K.	K.	(2009).	Depressive	Symptoms	and	Glycemic	Control	in	Adolescents	With	Type	1	Diabetes.	
Diabetes	Care,	32(5),	804–806.	doi:10.2337/dc08-2111	Menke,	A.,	Orchard,	T.	J.,	Imperatore,	G.,	Bullard,	K.	M.,	Mayer-Davis,	E.,	&	Cowie,	C.	C.	(2013).	The	Prevalence	of	Type	1	Diabetes	in	the	United	States.	Epidemiology	
(Cambridge,	Mass.),	24(5),	773–774.	doi:10.1097/EDE.0b013e31829ef01a	Miele,	A.,	Weiland,	K.,	&	Dungan,	K.	M.	(2012).	Clinical	Outcomes	Associated	with	Referral-Based	Continuous	Glucose	Monitoring	Using	a	Central	Standardized	Interpretation	Strategy.	Diabetes	Technology	&	Therapeutics,	14(9),	765–771.	doi:10.1089/dia.2012.0081	Miller,	K.	M.,	Foster,	N.	C.,	Beck,	R.	W.,	Bergenstal,	R.	M.,	DuBose,	S.	N.,	DiMeglio,	L.	A.,	…	Tamborlane,	W.	V.	(2015).	Current	State	of	Type	1	Diabetes	Treatment	in	the	U.S.:	Updated	Data	From	the	T1D	Exchange	Clinic	Registry.	Diabetes	Care,	
38(6),	971–978.	doi:10.2337/dc15-0078	Nair,	K.,	Dolovich,	L.,	Cassels,	A.,	McCormack,	J.,	Levine,	M.,	Gray,	J.,	…	Burns,	S.	(2002).	What	patients	want	to	know	about	their	medications.	Focus	group	study	of	patient	and	clinician	perspectives.	Canadian	Family	Physician,	48(1),	104–110.	National	Diabetes	Statistics	Report	|	Data	&	Statistics	|	Diabetes	|	CDC.	(2017,	July	17).	Retrieved	February	18,	2018,	from	https://www.cdc.gov/diabetes/data/statistics/statistics-report.html	
	32 
Phillip,	M.,	Battelino,	T.,	Rodriguez,	H.,	Danne,	T.,	&	Kaufman,	F.	(2007).	Use	of	Insulin	Pump	Therapy	in	the	Pediatric	Age-Group:	Consensus	statement	from	the	European	Society	for	Paediatric	Endocrinology,	the	Lawson	Wilkins	Pediatric	Endocrine	Society,	and	the	International	Society	for	Pediatric	and	Adolescent	Diabetes,	endorsed	by	the	American	Diabetes	Association	and	the	European	Association	for	the	Study	of	Diabetes.	Diabetes	Care,	30(6),	1653–1662.	doi:10.2337/dc07-9922	Piette,	J.	D.,	Heisler,	M.,	&	Wagner,	T.	H.	(2004).	Problems	Paying	Out-of-Pocket	Medication	Costs	Among	Older	Adults	With	Diabetes.	Diabetes	Care,	27(2),	384–391.	doi:10.2337/diacare.27.2.384	Rubin,	R.	R.,	&	Peyrot,	M.	(2009).	Treatment	Satisfaction	and	Quality	of	Life	for	an	Integrated	Continuous	Glucose	Monitoring/Insulin	Pump	System	Compared	to	Self-Monitoring	Plus	an	Insulin	Pump.	Journal	of	Diabetes	Science	and	
Technology,	3(6),	1402–1410.	doi:	10.1177/193229680900300621	
 Russell,	S.	J.	(2015).	Progress	of	artificial	pancreas	devices	toward	clinical	use:	the	first	outpatient	studies.	Current	Opinion	in	Endocrinology,	Diabetes,	and	
Obesity,	22(2),	106–111.	doi:10.1097/MED.0000000000000142	Scheiner,	G.,	Sobel,	R.	J.,	Smith,	D.	E.,	Pick,	A.	J.,	Kruger,	D.,	King,	J.,	&	Green,	K.	(2009).	Insulin	pump	therapy:	guidelines	for	successful	outcomes.	The	Diabetes	
Educator,	35	Suppl	2,	29S–41S;	quiz	28S,	42S–43S.	doi:10.1177/0145721709333493	
	33 
Scrimgeour,	L.,	Cobry,	E.,	McFann,	K.,	Burdick,	P.,	Weimer,	C.,	Slover,	R.,	&	Chase,	H.	P.	(2007).	Improved	Glycemic	Control	After	Long-Term	Insulin	Pump	Use	in	Pediatric	Patients	with	Type	1	Diabetes.	Diabetes	Technology	&	Therapeutics,	
9(5),	421–428.	doi:10.1089/dia.2007.0214	Seereiner,	S.,	Neeser,	K.,	Weber,	C.,	Schreiber,	K.,	Habacher,	W.,	Rakovac,	I.,	…	Pieber,	T.	R.	(2010).	Attitudes	Towards	Insulin	Pump	Therapy	Among	Adolescents	and	Young	People.	Diabetes	Technology	&	Therapeutics,	12(1),	89–94.	doi:10.1089/dia.2009.0080	Sharifi,	A.,	De	Bock,	M.	I.,	Jayawardene,	D.,	Loh,	M.	M.,	Horsburgh,	J.	C.,	Berthold,	C.	L.,	…	O’Neal,	D.	N.	(2016).	Glycemia,	Treatment	Satisfaction,	Cognition,	and	Sleep	Quality	in	Adults	and	Adolescents	with	Type	1	Diabetes	When	Using	a	Closed-Loop	System	Overnight	Versus	Sensor-Augmented	Pump	with	Low-Glucose	Suspend	Function:	A	Randomized	Crossover	Study.	Diabetes	
Technology	&	Therapeutics,	18(12),	772–783.	doi:10.1089/dia.2016.0288	Sherr,	J.	L.,	Hermann,	J.	M.,	Campbell,	F.,	Foster,	N.	C.,	Hofer,	S.	E.,	Allgrove,	J.,	…	T1D	Exchange	Clinic	Network,	the	DPV	Initiative,	and	the	National	Paediatric	Diabetes	Audit	and	the	Royal	College	of	Paediatrics	and	Child	Health	registries.	(2016).	Use	of	insulin	pump	therapy	in	children	and	adolescents	with	type	1	diabetes	and	its	impact	on	metabolic	control:	comparison	of	results	from	three	large,	transatlantic	paediatric	registries.	Diabetologia,	
59(1),	87–91.	doi:10.1007/s00125-015-3790-6	
	34 
Songer,	T.	J.,	LaPorte,	R.	E.,	Lave,	J.	R.,	Dorman,	J.	S.,	&	Becker,	D.	J.	(1997).	Health	Insurance	and	the	Financial	Impact	of	IDDM	in	Families	With	a	Child	With	IDDM.	Diabetes	Care,	20(4),	577–584.	doi:10.2337/diacare.20.4.577	Strum,	M.	W.,	Hopkins,	R.,	West,	D.	S.,	&	Harris,	B.	N.	(2005).	Effects	of	a	medication	assistance	program	on	health	outcomes	in	patients	with	type	2	diabetes	mellitus.	American	Journal	of	Health-System	Pharmacy:	AJHP:	Official	Journal	
of	the	American	Society	of	Health-System	Pharmacists,	62(10),	1048–1052.	doi:	10.18553/jmcp.2017.23.5.573	
 Tanenbaum,	M.	L.,	Adams,	R.	N.,	Barley,	R.	C.,	Hanes,	S.	J.,	Iturralde,	E.,	Naranjo,	D.,	…	Hood,	K.	K.	(2017).	Diabetes	Devices	and	Profiles	of	the	Clinicians	Who	Prescribe	Them.	Paper	Presented	at	the	American	Diabetes	Association	77th	
Scientific	Sessions.	Tanenbaum,	M.	L.,	Adams,	R.	N.,	Hanes,	S.	J.,	Barley,	R.	C.,	Miller,	K.	M.,	Mulvaney,	S.	A.,	&	Hood,	K.	K.	(2017).	Optimal	Use	of	Diabetes	Devices:	Clinician	Perspectives	on	Barriers	and	Adherence	to	Device	Use.	Journal	of	Diabetes	
Science	and	Technology,	11(3),	484–492.	doi:10.1177/1932296816688010	Tauschmann,	M.,	Allen,	J.	M.,	Wilinska,	M.	E.,	Thabit,	H.,	Acerini,	C.	L.,	Dunger,	D.	B.,	&	Hovorka,	R.	(2016).	Home	Use	of	Day-and-Night	Hybrid	Closed-Loop	Insulin	Delivery	in	Suboptimally	Controlled	Adolescents	With	Type	1	Diabetes:	A	3-Week,	Free-Living,	Randomized	Crossover	Trial.	Diabetes	Care,	39(11),	2019–2025.	doi:10.2337/dc16-1094	
	35 
Tauschmann,	M.,	Allen,	J.	M.,	Wilinska,	M.	E.,	Thabit,	H.,	Stewart,	Z.,	Cheng,	P.,	…	Hovorka,	R.	(2016).	Day-and-Night	Hybrid	Closed-Loop	Insulin	Delivery	in	Adolescents	With	Type	1	Diabetes:	A	Free-Living,	Randomized	Clinical	Trial.	
Diabetes	Care,	39(7),	1168–1174.	doi:10.2337/dc15-2078	Tauschmann,	M.,	&	Hovorka,	R.	(2017).	Glucose	Monitoring	and	Insulin	Pump	Therapy	in	the	Management	of	Children	and	Adolescents	with	Type	1	Diabetes.	In	Research	into	Childhood-Onset	Diabetes	(pp.	163–172).	Springer,	Cham.	doi:10.1007/978-3-319-40242-0_14	Vigersky,	R.	A.,	Fish,	L.,	Hogan,	P.,	Stewart,	A.,	Kutler,	S.,	Ladenson,	P.	W.,	…	Hupart,	K.	H.	(2014).	The	Clinical	Endocrinology	Workforce:	Current	Status	and	Future	Projections	of	Supply	and	Demand.	The	Journal	of	Clinical	Endocrinology	&	
Metabolism,	99(9),	3112–3121.	doi:10.1210/jc.2014-2257	Weinzimer,	S.	A.,	Ahern,	J.	H.,	Doyle,	E.	A.,	Vincent,	M.	R.,	Dziura,	J.,	Steffen,	A.	T.,	&	Tamborlane,	W.	V.	(2004).	Persistence	of	Benefits	of	Continuous	Subcutaneous	Insulin	Infusion	in	Very	Young	Children	With	Type	1	Diabetes:	A	Follow-up	Report.	Pediatrics,	114(6),	1601–1605.	doi:10.1542/peds.2004-0092	Weissberg-Benchell,	J.,	Antisdel-Lomaglio,	J.,	&	Seshadri,	R.	(2003).	Insulin	Pump	Therapy:	A	meta-analysis.	Diabetes	Care,	26(4),	1079–1087.	doi:10.2337/diacare.26.4.1079	Wong,	J.	C.,	Foster,	N.	C.,	Maahs,	D.	M.,	Raghinaru,	D.,	Bergenstal,	R.	M.,	Ahmann,	A.	J.,	…	T1D	Exchange	Clinic	Network.	(2014).	Real-time	continuous	glucose	
	36 
monitoring	among	participants	in	the	T1D	Exchange	clinic	registry.	Diabetes	
Care,	37(10),	2702–2709.	doi:10.2337/dc14-0303	Yarnall,	K.	S.	H.,	Pollak,	K.	I.,	Østbye,	T.,	Krause,	K.	M.,	&	Michener,	J.	L.	(2003).	Primary	care:	is	there	enough	time	for	prevention?	American	Journal	of	Public	
Health,	93(4),	635–641.	Zabeen,	B.,	Craig,	M.	E.,	Virk,	S.	A.,	Pryke,	A.,	Chan,	A.	K.	F.,	Cho,	Y.	H.,	…	Donaghue,	K.	C.	(2016).	Insulin	Pump	Therapy	Is	Associated	with	Lower	Rates	of	Retinopathy	and	Peripheral	Nerve	Abnormality.	PloS	One,	11(4),	e0153033.	doi:10.1371/journal.pone.0153033	Zgibor,	J.	C.,	&	Songer,	T.	J.	(2001).	External	Barriers	to	Diabetes	Care:	Addressing	Personal	and	Health	Systems	Issues.	Diabetes	Spectrum,	14(1),	23–28.	doi:10.2337/diaspect.14.1.23	
  
	37 
CURRICULUM VITAE 
	38 
	39 
